Inquiry Basket
CAS No.: 2245698-48-8
Cat No.: BADC-00011
Purity: ≥98%
4.5 
DM4 with a reactive linker SPDP, which can react with antibody to make antibody drug conjugate. DM4 can bind to tubulin at or near the vinblastine-binding site.
Structure of 2245698-48-8
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| 1 mg | $299 | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
DM4-SPDP, an potent cytotoxic agent linked to antibodies via a cleavable linker, plays a pivotal role in targeted cancer therapies. Here are four key applications of DM4-SPDP:
Antibody-Drug Conjugates (ADCs): Utilizing DM4-SPDP in the development of ADCs represents a cutting-edge approach to delivering cytotoxic drugs directly to cancerous cells. By conjugating DM4 to monoclonal antibodies that specifically target antigens on tumor cells, this strategy minimizes harm to normal tissues. The precision of this targeted therapy not only boosts the effectiveness of cancer treatments but also enhances their safety profile significantly.
Bioconjugation Research: In the realm of bioconjugation studies, researchers harness DM4-SPDP for crafting innovative drug delivery systems. The cleavable linker SPDP allows for precise release of the drug at the intended target location. This unique property proves critical for optimizing drug stability and fine-tuning release kinetics, particularly in therapeutic settings where precision is paramount.
Preclinical Cancer Models: DM4-SPDP finds extensive use in preclinical cancer models aimed at elucidating the mechanisms of action and resistance in cancer treatment. By incorporating it into diverse in vitro and in vivo models, scientists can thoroughly assess the anti-cancer efficacy of this compound while also evaluating potential side effects. These comprehensive studies serve as a vital stepping stone for advancing ADCs from preclinical research to pivotal clinical trials.
Synthetic Organic Chemistry: Beyond oncology, DM4-SPDP plays a key role in synthetic organic chemistry, offering a versatile tool for creating functionalized molecules. Its unique ability to form stable yet cleavable linkages makes it invaluable in constructing intricate molecular structures. Capitalizing on these distinctive properties, researchers leverage DM4-SPDP to design and synthesize groundbreaking therapeutics and diagnostic agents, pushing the boundaries of innovation in synthetic chemistry.
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-00017 | DM4-SMCC | 1228105-52-9 | |
| BADC-01467 | Lys-Nε-SPDB-DM4 | 1280215-91-9 | |
| BADC-00600 | Sulfo-PDBA-DM4 | 1461704-01-7 | |
| BADC-00018 | sulfo-SPDB-DM4 | 1626359-59-8 | |
| BADC-00012 | DM4-SPDB | 1626359-62-3 | |
| BADC-00021 | DM4-SMe | 796073-68-2 | |
| BADC-00347 | DM4 | 796073-69-3 | |
| BADC-00087 | Maytansinoid DM4 | 799840-96-3 | |
| BADC-01365 | S-Me-DM4 | 890654-03-2 | |
| BADC-00704 | DBA-DM4 | 905449-84-5 |
What is DM4-SPDP?
DM4-SPDP is a cleavable linker-payload used in the synthesis of antibody-drug conjugates (ADCs). It is comprised of a cleavable disulfide linker, N-Succinimidyl-3-(2-pyridyldithio)propionate (SPDP), and a potent cytotoxic payload, DM4. This system is designed for controlled release of the payload at the target site.
27/9/2019
Could you explain how the SPDP linker functions in ADCs?
The SPDP linker is a disulfide-based cleavable linker. It forms a disulfide bond with a cysteine residue on the antibody. This bond is designed to be stable in circulation but is susceptible to cleavage by reducing agents, such as glutathione, which are present at high concentrations inside tumor cells. This mechanism enables the release of the DM4 payload upon internalization.
8/7/2019
Could you advise what is the mechanism of action of the DM4 payload?
The DM4 payload is a maytansinoid, a potent class of antimitotic agents. Its mechanism of action involves the inhibition of tubulin polymerization, which disrupts the microtubule network within cancer cells. This leads to cell cycle arrest at the G2/M phase and subsequent apoptosis, or programmed cell death, in the targeted cells.
18/8/2021
Could you please share the key advantages of using a disulfide linker such as SPDP?
The primary advantage of a disulfide linker like SPDP is its targeted release mechanism. It exploits the difference in the redox potential between the bloodstream and the intracellular environment of tumor cells. The high concentration of reducing agents inside the cell leads to the efficient cleavage of the disulfide bond, ensuring that the payload is released where it is needed most, while remaining stable in circulation.
11/8/2017
Dear BOC Sciences, why is DM4-SPDP considered a suitable choice for ADC development?
DM4-SPDP is a suitable choice because it combines a stable, cleavable linker with a highly potent payload. The SPDP linker ensures the payload is released specifically within the targeted cell, minimizing off-target effects. The DM4 payload provides a strong cytotoxic effect, which is crucial for the efficacy of the ADC. This system has been used successfully in the development of clinically approved ADCs.
9/9/2020
— Dr. Peter Hall, Senior Scientist (USA)
DM4-SPDP demonstrated excellent solubility and purity, which facilitated precise linker conjugation.
18/8/2021
— Dr. Sophia Wright, ADC Chemist (UK)
We valued the rapid delivery of DM4-SPDP for time-sensitive preclinical studies.
9/9/2020
— Dr. Thomas Weber, Medicinal Chemist (Germany)
Technical guidance provided for DM4-SPDP helped optimize experimental conditions.
11/8/2017
— Dr. Emily Scott, Biochemist (Canada)
Batch-to-batch reliability of DM4-SPDP allowed consistent cytotoxicity assay results.
27/9/2019
— Dr. Daniel Lewis, Principal Investigator (USA)
High-purity DM4-SPDP supported multiple ADC conjugation protocols seamlessly.
— Dr. Claire Fontaine, ADC Scientist (France)
BOC Sciences’ expertise combined with DM4-SPDP quality enabled efficient research progression.
8/7/2019
DM4-SPDP
Required fields are marked with *
DM4-SPDP
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
